Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: A cohort study of patients in the Total Therapy clinical trials.
Danziger SA, McConnell M, Gockley J, Young MH, Rosenthal A, Schmitz F, Reiss DJ, Farmer P, Alapat DV, Singh A, Ashby C, Bauer M, Ren Y, Smith K, Couto SS, van Rhee F, Davies F, Zangari M, Petty N, Orlowski RZ, Dhodapkar MV, Copeland WB, Fox B, Hoering A, Fitch A, Newhall K, Barlogie B, Trotter MWB, Hershberg RM, Walker BA, Dervan AP, Ratushny AV, Morgan GJ. Danziger SA, et al. Among authors: copeland wb. PLoS Med. 2020 Nov 4;17(11):e1003323. doi: 10.1371/journal.pmed.1003323. eCollection 2020 Nov. PLoS Med. 2020. PMID: 33147277 Free PMC article. Clinical Trial.
A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromes.
Zeidan AM, Boss I, Beach CL, Copeland WB, Thompson E, Fox BA, Hasle VE, Ogasawara K, Cavenagh J, Silverman LR, Voso MT, Hellmann A, Tormo M, O'Connor T, Previtali A, Rose S, Garcia-Manero G. Zeidan AM, et al. Among authors: copeland wb. Blood Adv. 2022 Apr 12;6(7):2207-2218. doi: 10.1182/bloodadvances.2021005487. Blood Adv. 2022. PMID: 34972214 Free PMC article. Clinical Trial.
A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML.
Zeidan AM, Boss I, Beach CL, Copeland WB, Thompson E, Fox BA, Hasle VE, Hellmann A, Taussig DC, Tormo M, Voso MT, Cavenagh J, O'Connor T, Previtali A, Rose S, Silverman LR. Zeidan AM, et al. Among authors: copeland wb. Blood Adv. 2022 Apr 12;6(7):2219-2229. doi: 10.1182/bloodadvances.2021006138. Blood Adv. 2022. PMID: 34933333 Free PMC article. Clinical Trial.
Increasing gender diversity in the STEM research workforce.
Greider CW, Sheltzer JM, Cantalupo NC, Copeland WB, Dasgupta N, Hopkins N, Jansen JM, Joshua-Tor L, McDowell GS, Metcalf JL, McLaughlin B, Olivarius A, O'Shea EK, Raymond JL, Ruebain D, Steitz JA, Stillman B, Tilghman SM, Valian V, Villa-Komaroff L, Wong JY. Greider CW, et al. Among authors: copeland wb. Science. 2019 Nov 8;366(6466):692-695. doi: 10.1126/science.aaz0649. Science. 2019. PMID: 31699926 No abstract available.
Reaction of CO2 with UO3 Nanoclusters.
Flores LA, Murphy JG, Copeland WB, Dixon DA. Flores LA, et al. Among authors: copeland wb. J Phys Chem A. 2017 Nov 9;121(44):8518-8524. doi: 10.1021/acs.jpca.7b09107. Epub 2017 Oct 25. J Phys Chem A. 2017. PMID: 29028336
Computational tools for metabolic engineering.
Copeland WB, Bartley BA, Chandran D, Galdzicki M, Kim KH, Sleight SC, Maranas CD, Sauro HM. Copeland WB, et al. Metab Eng. 2012 May;14(3):270-80. doi: 10.1016/j.ymben.2012.03.001. Metab Eng. 2012. PMID: 22629572 Free PMC article. Review.
Mathematical modeling and synthetic biology.
Chandran D, Copeland WB, Sleight SC, Sauro HM. Chandran D, et al. Among authors: copeland wb. Drug Discov Today Dis Models. 2008 Winter;5(4):299-309. doi: 10.1016/j.ddmod.2009.07.002. Drug Discov Today Dis Models. 2008. PMID: 27840651 Free PMC article.